NCT02494349View on ClinicalTrials.gov

The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
LUTS(Lower Urinary Tract Symptoms)Benign Prostatic HyperplasiaOveractive Bladder
Interventions
DRUG

JLP-1207

The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.

DRUG

Solifenacin 5mg+Tamsulosin 0.2mg

The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

NCT02494349 - The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. | Biotech Hunter | Biotech Hunter